Modality
Fusion Protein
MOA
SHP2i
Target
PRMT5
Pathway
Incretin
Prostate CaNarcolepsy
Development Pipeline
Preclinical
~Apr 2022
→ ~Jul 2023
Phase 1
Oct 2023
→ Dec 2030
Phase 1Current
NCT03626571
2,699 pts·Prostate Ca
2024-04→TBD·Not yet recruiting
NCT08554332
178 pts·Narcolepsy
2023-10→2030-12·Recruiting
2,877 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-12-034.7y awayInterim· Narcolepsy
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1
Recruit…
P1
Not yet…
Catalysts
Interim
2030-12-03 · 4.7y away
Narcolepsy
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03626571 | Phase 1 | Prostate Ca | Not yet recr... | 2699 | SeizFreq |
| NCT08554332 | Phase 1 | Narcolepsy | Recruiting | 178 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Doxacagene | Sanofi | Approved | PSMA | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET |